risankizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
humanized origin	5337	1612838-76-2

Description:

Molecule	Description
Synonyms: risankizumab skyrizi BI655066 655066-01 ABBV-066 BI-655066 risankizumab-rzaa	Skyrizi is a medicine used to treat plaque psoriasis, a disease causing red, scaly patches on the skin. Indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

risankizumab
skyrizi
BI655066
655066-01
ABBV-066
BI-655066
risankizumab-rzaa

Skyrizi is a medicine used to treat plaque psoriasis, a disease causing red, scaly patches on the skin. Indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
1.67	mg	P

ADMET properties:

None

Approvals:

Date	Agency	Company
April 26, 2019	EMA	AbbVie Deutschland GmbH & Co KG
April 23, 2019	FDA	AbbVie INC
March 26, 2019	PMDA	AbbVie Deutschland GmbH & Co KG

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
COVID-19	194.33	23.05	105	3567	112998	63372352
Drug ineffective	125.63	23.05	218	3454	1044547	62440803
Maternal exposure during pregnancy	62.51	23.05	70	3602	219992	63265358
Therapy interrupted	52.37	23.05	29	3643	32426	63452924
Psoriasis	52.36	23.05	42	3630	86915	63398435
Surgery	36.87	23.05	24	3648	35888	63449462
Inflammatory bowel disease	35.72	23.05	12	3660	3961	63481389
Paternal exposure during pregnancy	34.54	23.05	6	3666	115	63485235
Skin plaque	33.69	23.05	14	3658	8306	63477044
Death	32.93	23.05	69	3603	374312	63111038
Device defective	30.49	23.05	9	3663	1953	63483397
Pruritus	29.91	23.05	65	3607	361388	63123962
Abortion spontaneous	28.81	23.05	23	3649	47172	63438178
Pustule	27.30	23.05	8	3664	1691	63483659
Psoriatic arthropathy	25.70	23.05	29	3643	91491	63393859
Urinary tract infection	24.65	23.05	50	3622	264634	63220716

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
COVID-19	105.88	23.39	72	2971	77478	34876410
Drug ineffective	82.91	23.39	144	2899	456607	34497281
Dermatitis exfoliative generalised	75.54	23.39	23	3020	3684	34950204
Psoriasis	57.54	23.39	38	3005	38774	34915114
Skin plaque	43.40	23.39	16	3027	4598	34949290
Death	36.07	23.39	95	2948	397954	34555934
Therapy interrupted	34.85	23.39	19	3024	13678	34940210
Therapeutic response shortened	32.89	23.39	15	3028	7389	34946499
SARS-CoV-2 test positive	32.74	23.39	14	3029	5919	34947969
Botryomycosis	31.36	23.39	5	3038	35	34953853
Pityriasis rubra pilaris	26.26	23.39	5	3038	106	34953782
Basal cell carcinoma	26.11	23.39	18	3025	19640	34934248
Lung cancer metastatic	23.78	23.39	9	3034	2778	34951110

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
COVID-19	263.00	21.36	145	4612	157529	79582102
Therapy interrupted	84.55	21.36	40	4717	31301	79708330
Psoriasis	67.36	21.36	50	4707	89537	79650094
Skin plaque	56.48	21.36	22	4735	10723	79728908
Dermatitis exfoliative generalised	38.67	21.36	15	4742	7226	79732405
SARS-CoV-2 test positive	37.98	21.36	17	4740	11699	79727932
Psoriatic arthropathy	32.52	21.36	31	4726	77968	79661663
Lung cancer metastatic	32.23	21.36	11	4746	3688	79735943
Inflammatory bowel disease	31.22	21.36	12	4745	5639	79733992
Device defective	30.40	21.36	9	4748	1911	79737720
Pustule	29.93	21.36	9	4748	2016	79737615
Basal cell carcinoma	28.36	21.36	21	4736	37354	79702277
Death	25.63	21.36	83	4674	566431	79173200
Thrombosis prophylaxis	25.06	21.36	4	4753	43	79739588
Botryomycosis	23.82	21.36	4	4753	60	79739571
Cutaneous T-cell lymphoma	23.40	21.36	8	4749	2695	79736936
Prosthesis implantation	22.46	21.36	4	4753	86	79739545
Urinary tract infection	22.31	21.36	50	4707	274462	79465169

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L04AC18	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Interleukin inhibitors
FDA MoA	N0000192798	Interleukin-23 Antagonists
FDA EPC	N0000192799	Interleukin-23 Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Psoriasis	indication	9014002	DOID:8893
Crohn's disease	indication	34000006
Psoriatic arthritis	indication	156370009	DOID:9008
Plaque psoriasis	indication	200965009
Pustular psoriasis	indication	200973000
Erythrodermic psoriasis	indication	200977004

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Interleukin-23 subunit alpha	Cytokine	Q9NPF7	IL23A_HUMAN	INHIBITOR	Kd	11		SCIENTIFIC LITERATURE	DRUG LABEL

External reference:

ID	Source
90ZX3Q3FR7	UNII
C4505511	UMLSCUI
CHEMBL3990029	ChEMBL_ID
DB14762	DRUGBANK_ID
D11052	KEGG_DRUG
10128	INN_ID
8922	IUPHAR_LIGAND_ID
017980	NDDF
787732000	SNOMEDCT_US
787746000	SNOMEDCT_US
4038346	VANDF
2166040	RXNORM
314451	MMSL
36772	MMSL
36774	MMSL
d09243	MMSL
C000601773	MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Skyrizi	HUMAN PRESCRIPTION DRUG LABEL	1	0074-1050	INJECTION	150 mg	SUBCUTANEOUS	BLA	31 sections
Skyrizi	HUMAN PRESCRIPTION DRUG LABEL	1	0074-1050	INJECTION	150 mg	SUBCUTANEOUS	BLA	31 sections
Skyrizi	HUMAN PRESCRIPTION DRUG LABEL	1	0074-1050	INJECTION	150 mg	SUBCUTANEOUS	BLA	31 sections
Skyrizi	HUMAN PRESCRIPTION DRUG LABEL	1	0074-2100	INJECTION	150 mg	SUBCUTANEOUS	BLA	31 sections
Skyrizi	HUMAN PRESCRIPTION DRUG LABEL	1	0074-2100	INJECTION	150 mg	SUBCUTANEOUS	BLA	31 sections
Skyrizi	HUMAN PRESCRIPTION DRUG LABEL	1	0074-2100	INJECTION	150 mg	SUBCUTANEOUS	BLA	31 sections
Skyrizi	HUMAN PRESCRIPTION DRUG LABEL	1	0074-5015	INJECTION	600 mg	INTRAVENOUS	BLA	31 sections
Skyrizi	HUMAN PRESCRIPTION DRUG LABEL	1	0074-5015	INJECTION	60 mg	INTRAVENOUS	BLA	31 sections